← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Netherlands Cancer Institute
Amsterdam
$1,636,915
Total funding
5
Grants
Funding over time
peak $488.8K · FY2007–25$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,636,915 · 5
By mechanism
R37$648,296 · 1
R01$639,089 · 1
OT2$167,757 · 1
R03$109,468 · 1
R21$72,305 · 1
Investigators at Netherlands Cancer Institute
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast cancer risk$321,003
R37 · FY2024 · CA
Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast cancer risk$265,730
R37 · FY2025 · CA
The role of the Hippo pathway on mammalian organ size, progenitor cells and cance$217,377
R01 · FY2012 · CA
The role of the Hippo pathway on mammalian organ size, progenitor cells and cance$217,377
R01 · FY2011 · CA
The role of the Hippo pathway on mammalian organ size, progenitor cells and cance$204,335
R01 · FY2013 · CA
MATCHMAKERS$167,757
OT2 · FY2024 · CA
SIGNIFICANCE OF HYPOXIA IN HUMAN TUMORS OF THE HEAD$72,305
R21 · FY2000 · CA
Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast cancer risk$61,563
R37 · FY2025 · CA
Risk and prognosis of uterine corpus cancer after tamoxifen treatment for breast$54,734
R03 · FY2008 · CA
Risk and prognosis of uterine corpus cancer after tamoxifen treatment for breast$54,734
R03 · FY2007 · CA